Evidence map›Paper›PMID 40936712›Full record

ArticleFrontiers in oncology2025

Leung Li, Nelson L S Tang, Frankie Mo, Jane Koh, Edwin P Hui, Brigette Ma, Stephen L Chan, Kit F Lee, Simon C H Yu, Winnie Yeo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leung LiState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Nelson L S TangState Key Laboratory of Translational Oncology, Department of Chemical Pathology, Prince of Wales Hospital, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Frankie MoState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Jane KohState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Edwin P HuiState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Brigette MaState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Stephen L ChanState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Kit F LeeDepartment of Surgery, Prince of Wales Hospital, Shatin, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Simon C H YuDepartment of Diagnostic and Interventional Radiology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Winnie YeoState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: An increasing number of immuno-therapeutic agents have proven efficacy in hepatocellular carcinoma (HCC). Inflammatory markers (c-reactive protein, interleukin-8 and inflammatory score) have been found to be prognostic factors in HCC patients. These inflammatory markers have demonstrated correlations with quality of life (QOL) disturbances in fatigue, appetite loss and nutritional concern. Type I interferon response triggered by HCC could be responsible for an inflammatory state and anorexia-cachexia syndrome leading to these specific QOL impairment. Peripheral blood Interferon Stimulated Gene 15 ( Methods: Clinical, QOL and laboratory data of 340 treatment naïve HCC patients were collected at study entry. Results: High Conclusions: Elevated

Indexed as

anorexia cachexia syndromecDNAEORTC QLQ-C30HCC18 index scoreinterferon stimulated gene 15liver cancerqPCRtype I interferon response

Identifiers

PMID40936712
PMCPMC12420207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.